2025 Q4 -tulosraportti
Vain PDF
19 päivää sitten
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 20 | - | - | ||
| 759 | - | - | ||
| 2 041 | - | - | ||
| 1 000 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 305 562 | 305 562 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 305 562 | 305 562 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenAs Secondwind has pointed out, a large part of the selling pressure in Stenocare can possibly be explained by DanCann, which received approx. 5 million shares in connection with the sale of CannGros to Stenocare. The transaction was completed on November 17, 2025, and the new shares began trading on the stock exchange on November 19. This gave DanCann an ownership stake of approximately 11-12 % of the company. If DanCann has since chosen to reduce or divest their position, this alone can create significant selling pressure. For a small cap like Stenocare, 5 million shares is a very large quantity compared to the normal daily volume. The interesting question is therefore not only whether DanCann has sold – but how much they have already sold. If they no longer appear as a major shareholder, it practically means that their ownership stake has fallen below 5 %. This implies that a minimum of approximately 2.8 million shares have been sold, based on the current number of outstanding shares. https://www.tradingview.com/x/9xkhvXnl/·5 t sitten3D, it will take months to sell 5 million shares, as the liquidity is very low.. So yes, in my opinion, it could still be them selling off.- ·12.3.Technical analysis d. 12/3/26 https://www.tradingview.com/x/WHNc1Ya1/https://www.tradingview.com/x/uzorteqk/ Overall, I still see the market trading within a larger range between approx. 1,045 and 1,68. Since 12. januar, the price has formed a descending triangle, which broke down at the end of February. The backtest in early March was rejected, and the price is now continuing down towards 1,125. The structure continues to show weakness, and 1,30, which was previously support, has now turned into resistance. My base case is therefore that the price tests the bottom of the range around 1,045, as long as the resistance zone at 1,3 holds. The saying typically goes: 'Trade the range until it breaks.'
·11.3.CANTOURAGE GROUP SE In light of the latest developments in the European cannabis industry, both NuWays and Montega have, in connection with their coverage of Cantourage Group, chosen to upgrade their price targets, which now lie in the range of EUR 8.00-10.00 per share. This reflects a potential price increase of approx. 70-90 % from the current level. The analysis coverage fully aligns with my own observations - and is possibly even a bit conservative compared to my personal estimate of EUR 10.00-12.00 per share at present. The analyses can be found at the following links: NuWays AG (published on March 9, 2026): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/69afd9c9f30a9bf33e547314_Cantourage_Update.pdf Montega AG (published on March 9, 2026): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/69aef696a4cfffe001fb1002_af05aa5c-e8db-4d6d-adda-ed4eb6810d16.pdf7 t sitten7 t sittenModtaget denne morgen: "Cantourage Group SE / Key word(s): Annual Results/Preliminary Results Cantourage Group SE publishes preliminary figures for 2025 – Revenue rises to EUR 92.8 million 17.03.2026 CET/CEST Cantourage Group SE (ISIN: DE000A3DSV01) today published preliminary consolidated figures for the 2025 financial year. During the reporting period, the company achieved a significant increase in both revenue and earnings, thereby continuing its dynamic growth trajectory as one of the leading European companies in the field of medical cannabis. Group revenue increased to EUR 92.8 million in the 2025 financial year (previous year: EUR 50.9 million), representing growth of 82.3% compared to the previous year. Preliminary EBITDA rose to EUR 5.7 million (previous year: EUR 3.8 million)." International expansion supports sustainable earnings quality Strategic expansion into selected core European markets is increasingly contributing to improved revenue and earnings. Business in the United Kingdom continued to develop positively and accounted for more than 20% of total group revenue in the 2025 financial year. The positioning of Cantourage Group SE as a pan-European pharmaceutical company is showing increasingly positive effects. Economies of scale, optimized supply chains, and a diversified market presence are stabilizing operational development. “The European medical cannabis market is increasingly entering a new phase of growth. With our scalable sourcing and distribution platform, exclusive supplier partnerships, and regulatory expertise, we are ideally positioned to benefit from this development. Our focus is on meeting rising demand in our core markets, further expanding our capacities, and establishing Cantourage as one of the leading companies in all relevant European medical markets,” explains Philip Schetter, CEO of Cantourage Group SE."
·10.3.Does anyone know who the seller is of the 500 thousand that are out now?
·2 päivää sittenI think DanCann has divested their shares over a longer period in connection with the sale of Canngros, which has contributed to pushing the price down - see possibly: https://lasso.dk/firmaer/39024705/stenocare-as-ndrer-ejerstruktur-s-dancann-pharma-as-ikke-lngere-er-ejer/b3duZW5kfENWUi0xLTM5MDI0NzA1fFExWlNMVEV0TXprME1qWXdNRFY4TXk0MmZERXhMekUzTHpJd0JqVWdNVEk2TURBNk1EQWdRVTE4TUM0eGZGWmhiSFZs
·10.3.As expected, Q4 was no boost for Stenocare. For that, the report was too weak overall. The share price is pointing downwards, and technically, the support around 1.3 is also broken. That makes the way back up a bit harder as we now meet resistance there. Unless we get some positive fundamental news, I don't foresee any rise in the near future. And then there was the financing need. Money must be in place soon one way or another. I probably won't buy more Stenocare until I know how the company will solve it.·10.3.I think they increase their revenue with the measures they have taken and thereby also more cash flow On days before news and financial reports, the stock is sometimes traded higher, which can be incomprehensible So news or not Apparently, it only takes a little bad publicity for people to panic and sell If the price starts to gain momentum, they jump on the bandwagon and buy without news 🤔 I myself have bought in several rounds And I'm happy to wait Stocks can go both ways, and one must be aware that loss and patience must be accepted·10.3.I naturally agree with you that one must be patient if one is to succeed in the stock market, and it's far from always going up. I still have my shares in the company intact as I still haven't lost faith that this will eventually work out. But the path upwards might seem a bit tougher than I thought when I made my first purchase. I will probably wait for a couple more reports before I eventually sell out.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
19 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenAs Secondwind has pointed out, a large part of the selling pressure in Stenocare can possibly be explained by DanCann, which received approx. 5 million shares in connection with the sale of CannGros to Stenocare. The transaction was completed on November 17, 2025, and the new shares began trading on the stock exchange on November 19. This gave DanCann an ownership stake of approximately 11-12 % of the company. If DanCann has since chosen to reduce or divest their position, this alone can create significant selling pressure. For a small cap like Stenocare, 5 million shares is a very large quantity compared to the normal daily volume. The interesting question is therefore not only whether DanCann has sold – but how much they have already sold. If they no longer appear as a major shareholder, it practically means that their ownership stake has fallen below 5 %. This implies that a minimum of approximately 2.8 million shares have been sold, based on the current number of outstanding shares. https://www.tradingview.com/x/9xkhvXnl/·5 t sitten3D, it will take months to sell 5 million shares, as the liquidity is very low.. So yes, in my opinion, it could still be them selling off.
- ·12.3.Technical analysis d. 12/3/26 https://www.tradingview.com/x/WHNc1Ya1/https://www.tradingview.com/x/uzorteqk/ Overall, I still see the market trading within a larger range between approx. 1,045 and 1,68. Since 12. januar, the price has formed a descending triangle, which broke down at the end of February. The backtest in early March was rejected, and the price is now continuing down towards 1,125. The structure continues to show weakness, and 1,30, which was previously support, has now turned into resistance. My base case is therefore that the price tests the bottom of the range around 1,045, as long as the resistance zone at 1,3 holds. The saying typically goes: 'Trade the range until it breaks.'
- ·11.3.CANTOURAGE GROUP SE In light of the latest developments in the European cannabis industry, both NuWays and Montega have, in connection with their coverage of Cantourage Group, chosen to upgrade their price targets, which now lie in the range of EUR 8.00-10.00 per share. This reflects a potential price increase of approx. 70-90 % from the current level. The analysis coverage fully aligns with my own observations - and is possibly even a bit conservative compared to my personal estimate of EUR 10.00-12.00 per share at present. The analyses can be found at the following links: NuWays AG (published on March 9, 2026): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/69afd9c9f30a9bf33e547314_Cantourage_Update.pdf Montega AG (published on March 9, 2026): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/69aef696a4cfffe001fb1002_af05aa5c-e8db-4d6d-adda-ed4eb6810d16.pdf7 t sitten7 t sittenModtaget denne morgen: "Cantourage Group SE / Key word(s): Annual Results/Preliminary Results Cantourage Group SE publishes preliminary figures for 2025 – Revenue rises to EUR 92.8 million 17.03.2026 CET/CEST Cantourage Group SE (ISIN: DE000A3DSV01) today published preliminary consolidated figures for the 2025 financial year. During the reporting period, the company achieved a significant increase in both revenue and earnings, thereby continuing its dynamic growth trajectory as one of the leading European companies in the field of medical cannabis. Group revenue increased to EUR 92.8 million in the 2025 financial year (previous year: EUR 50.9 million), representing growth of 82.3% compared to the previous year. Preliminary EBITDA rose to EUR 5.7 million (previous year: EUR 3.8 million)." International expansion supports sustainable earnings quality Strategic expansion into selected core European markets is increasingly contributing to improved revenue and earnings. Business in the United Kingdom continued to develop positively and accounted for more than 20% of total group revenue in the 2025 financial year. The positioning of Cantourage Group SE as a pan-European pharmaceutical company is showing increasingly positive effects. Economies of scale, optimized supply chains, and a diversified market presence are stabilizing operational development. “The European medical cannabis market is increasingly entering a new phase of growth. With our scalable sourcing and distribution platform, exclusive supplier partnerships, and regulatory expertise, we are ideally positioned to benefit from this development. Our focus is on meeting rising demand in our core markets, further expanding our capacities, and establishing Cantourage as one of the leading companies in all relevant European medical markets,” explains Philip Schetter, CEO of Cantourage Group SE."
- ·10.3.Does anyone know who the seller is of the 500 thousand that are out now?·2 päivää sittenI think DanCann has divested their shares over a longer period in connection with the sale of Canngros, which has contributed to pushing the price down - see possibly: https://lasso.dk/firmaer/39024705/stenocare-as-ndrer-ejerstruktur-s-dancann-pharma-as-ikke-lngere-er-ejer/b3duZW5kfENWUi0xLTM5MDI0NzA1fFExWlNMVEV0TXprME1qWXdNRFY4TXk0MmZERXhMekUzTHpJd0JqVWdNVEk2TURBNk1EQWdRVTE4TUM0eGZGWmhiSFZs
- ·10.3.As expected, Q4 was no boost for Stenocare. For that, the report was too weak overall. The share price is pointing downwards, and technically, the support around 1.3 is also broken. That makes the way back up a bit harder as we now meet resistance there. Unless we get some positive fundamental news, I don't foresee any rise in the near future. And then there was the financing need. Money must be in place soon one way or another. I probably won't buy more Stenocare until I know how the company will solve it.·10.3.I think they increase their revenue with the measures they have taken and thereby also more cash flow On days before news and financial reports, the stock is sometimes traded higher, which can be incomprehensible So news or not Apparently, it only takes a little bad publicity for people to panic and sell If the price starts to gain momentum, they jump on the bandwagon and buy without news 🤔 I myself have bought in several rounds And I'm happy to wait Stocks can go both ways, and one must be aware that loss and patience must be accepted·10.3.I naturally agree with you that one must be patient if one is to succeed in the stock market, and it's far from always going up. I still have my shares in the company intact as I still haven't lost faith that this will eventually work out. But the path upwards might seem a bit tougher than I thought when I made my first purchase. I will probably wait for a couple more reports before I eventually sell out.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 20 | - | - | ||
| 759 | - | - | ||
| 2 041 | - | - | ||
| 1 000 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 305 562 | 305 562 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 305 562 | 305 562 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
19 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 30.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenAs Secondwind has pointed out, a large part of the selling pressure in Stenocare can possibly be explained by DanCann, which received approx. 5 million shares in connection with the sale of CannGros to Stenocare. The transaction was completed on November 17, 2025, and the new shares began trading on the stock exchange on November 19. This gave DanCann an ownership stake of approximately 11-12 % of the company. If DanCann has since chosen to reduce or divest their position, this alone can create significant selling pressure. For a small cap like Stenocare, 5 million shares is a very large quantity compared to the normal daily volume. The interesting question is therefore not only whether DanCann has sold – but how much they have already sold. If they no longer appear as a major shareholder, it practically means that their ownership stake has fallen below 5 %. This implies that a minimum of approximately 2.8 million shares have been sold, based on the current number of outstanding shares. https://www.tradingview.com/x/9xkhvXnl/·5 t sitten3D, it will take months to sell 5 million shares, as the liquidity is very low.. So yes, in my opinion, it could still be them selling off.
- ·12.3.Technical analysis d. 12/3/26 https://www.tradingview.com/x/WHNc1Ya1/https://www.tradingview.com/x/uzorteqk/ Overall, I still see the market trading within a larger range between approx. 1,045 and 1,68. Since 12. januar, the price has formed a descending triangle, which broke down at the end of February. The backtest in early March was rejected, and the price is now continuing down towards 1,125. The structure continues to show weakness, and 1,30, which was previously support, has now turned into resistance. My base case is therefore that the price tests the bottom of the range around 1,045, as long as the resistance zone at 1,3 holds. The saying typically goes: 'Trade the range until it breaks.'
- ·11.3.CANTOURAGE GROUP SE In light of the latest developments in the European cannabis industry, both NuWays and Montega have, in connection with their coverage of Cantourage Group, chosen to upgrade their price targets, which now lie in the range of EUR 8.00-10.00 per share. This reflects a potential price increase of approx. 70-90 % from the current level. The analysis coverage fully aligns with my own observations - and is possibly even a bit conservative compared to my personal estimate of EUR 10.00-12.00 per share at present. The analyses can be found at the following links: NuWays AG (published on March 9, 2026): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/69afd9c9f30a9bf33e547314_Cantourage_Update.pdf Montega AG (published on March 9, 2026): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/69aef696a4cfffe001fb1002_af05aa5c-e8db-4d6d-adda-ed4eb6810d16.pdf7 t sitten7 t sittenModtaget denne morgen: "Cantourage Group SE / Key word(s): Annual Results/Preliminary Results Cantourage Group SE publishes preliminary figures for 2025 – Revenue rises to EUR 92.8 million 17.03.2026 CET/CEST Cantourage Group SE (ISIN: DE000A3DSV01) today published preliminary consolidated figures for the 2025 financial year. During the reporting period, the company achieved a significant increase in both revenue and earnings, thereby continuing its dynamic growth trajectory as one of the leading European companies in the field of medical cannabis. Group revenue increased to EUR 92.8 million in the 2025 financial year (previous year: EUR 50.9 million), representing growth of 82.3% compared to the previous year. Preliminary EBITDA rose to EUR 5.7 million (previous year: EUR 3.8 million)." International expansion supports sustainable earnings quality Strategic expansion into selected core European markets is increasingly contributing to improved revenue and earnings. Business in the United Kingdom continued to develop positively and accounted for more than 20% of total group revenue in the 2025 financial year. The positioning of Cantourage Group SE as a pan-European pharmaceutical company is showing increasingly positive effects. Economies of scale, optimized supply chains, and a diversified market presence are stabilizing operational development. “The European medical cannabis market is increasingly entering a new phase of growth. With our scalable sourcing and distribution platform, exclusive supplier partnerships, and regulatory expertise, we are ideally positioned to benefit from this development. Our focus is on meeting rising demand in our core markets, further expanding our capacities, and establishing Cantourage as one of the leading companies in all relevant European medical markets,” explains Philip Schetter, CEO of Cantourage Group SE."
- ·10.3.Does anyone know who the seller is of the 500 thousand that are out now?·2 päivää sittenI think DanCann has divested their shares over a longer period in connection with the sale of Canngros, which has contributed to pushing the price down - see possibly: https://lasso.dk/firmaer/39024705/stenocare-as-ndrer-ejerstruktur-s-dancann-pharma-as-ikke-lngere-er-ejer/b3duZW5kfENWUi0xLTM5MDI0NzA1fFExWlNMVEV0TXprME1qWXdNRFY4TXk0MmZERXhMekUzTHpJd0JqVWdNVEk2TURBNk1EQWdRVTE4TUM0eGZGWmhiSFZs
- ·10.3.As expected, Q4 was no boost for Stenocare. For that, the report was too weak overall. The share price is pointing downwards, and technically, the support around 1.3 is also broken. That makes the way back up a bit harder as we now meet resistance there. Unless we get some positive fundamental news, I don't foresee any rise in the near future. And then there was the financing need. Money must be in place soon one way or another. I probably won't buy more Stenocare until I know how the company will solve it.·10.3.I think they increase their revenue with the measures they have taken and thereby also more cash flow On days before news and financial reports, the stock is sometimes traded higher, which can be incomprehensible So news or not Apparently, it only takes a little bad publicity for people to panic and sell If the price starts to gain momentum, they jump on the bandwagon and buy without news 🤔 I myself have bought in several rounds And I'm happy to wait Stocks can go both ways, and one must be aware that loss and patience must be accepted·10.3.I naturally agree with you that one must be patient if one is to succeed in the stock market, and it's far from always going up. I still have my shares in the company intact as I still haven't lost faith that this will eventually work out. But the path upwards might seem a bit tougher than I thought when I made my first purchase. I will probably wait for a couple more reports before I eventually sell out.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 20 | - | - | ||
| 759 | - | - | ||
| 2 041 | - | - | ||
| 1 000 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 305 562 | 305 562 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 305 562 | 305 562 | 0 | 0 |